{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:23:13Z","timestamp":1790288593497,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03282-9","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:12:44Z","timestamp":1755864764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAR-T cell therapy in china: innovations,\u00a0challenges, and strategic pathways"],"prefix":"10.1007","volume":"16","author":[{"given":"Lihui","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"1","key":"3282_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"3282_CR2","doi-asserted-by":"crossref","unstructured":"Reiss KA, Angelos MG, Dees EC et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 22025;31:1171\u20131182.","DOI":"10.1038\/s41591-025-03495-z"},{"key":"3282_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN, et al. Long-term outcomes following CAR T cell therapy: what we know so Far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3282_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/cancers11091339","volume":"11","author":"T Nishida","year":"2019","unstructured":"Nishida T, Kataoka H, et al. Glypican 3-Targeted therapy in hepatocellular carcinoma. Cancers (Basel). 2019;11(9):1339.","journal-title":"Cancers (Basel)"},{"key":"3282_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, et al. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287\u2013305.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"3282_CR6","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","volume":"30","author":"AM Barrett","year":"2024","unstructured":"Barrett AM, Britton ZT, Carrasco RA, et al. Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers. Clin Cancer Res. 2024;30(23):5413\u201329.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3282_CR7","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/cancers12092567","volume":"12","author":"N Schaft","year":"2020","unstructured":"Schaft N, et al. The landscape of CAR-T cell clinical trials against solid Tumors-A comprehensive overview. Cancers (Basel). 2020;12(9):2567.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3282_CR8","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, et al. Claudin18.2-specific CAR T cells in Gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224\u201334.","journal-title":"Nat Med"},{"issue":"1","key":"3282_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1142\/S0192415X18500027","volume":"46","author":"CS Cheng","year":"2018","unstructured":"Cheng CS, Chen J, Tan HY, et al. Scutellaria baicalensis and cancer treatment: recent progress and perspectives in biomedical and clinical studies. Am J Chin Med. 2018;46(1):25\u201354.","journal-title":"Am J Chin Med"},{"issue":"Pt 2","key":"3282_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.semcancer.2022.03.020","volume":"86","author":"I Kaushik","year":"2022","unstructured":"Kaushik I, Ramachandran S, Zabel C, et al. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol. 2022;86(Pt 2):491\u20138.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"3282_CR11","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, et al. CRISPR\/Cas9-Engineered universal CD19\/CD22 Dual-Targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764\u201372.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3282_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3282_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu W, Zi Z, Jin Y, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 2019;68(3):365\u201377.","journal-title":"Cancer Immunol Immunother"},{"issue":"6574","key":"3282_CR14","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng L, Qin S, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374(6574):abe6474.","journal-title":"Science"},{"issue":"1","key":"3282_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","volume":"17","author":"R Tan","year":"2024","unstructured":"Tan R, Li R, Dai MY, et al. Redefining chimeric antigen receptor T-cell (CAR-T) regulation: china\u2019s responses to address secondary cancer risks of CAR-T therapy. J Hematol Oncol. 2024;17(1):90.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3282_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/08830185.2022.2080820","volume":"41","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zu C, Hu Y, et al. CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through. Int Rev Immunol. 2022;41(6):567\u201381.","journal-title":"Int Rev Immunol"},{"issue":"5","key":"3282_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.seminhematol.2024.08.005","volume":"61","author":"O Castaneda Puglianini","year":"2024","unstructured":"Castaneda Puglianini O, Chavez JC, et al. CARs moving forward: the development of CAR T-Cell therapy in the earlier treatment course of hematologic malignancies. Semin Hematol. 2024;61(5):290\u20136.","journal-title":"Semin Hematol"},{"issue":"2","key":"3282_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/ph18020156","volume":"18","author":"A Hern\u00e1ndez-L\u00f3pez","year":"2025","unstructured":"Hern\u00e1ndez-L\u00f3pez A, Olaya-Vargas A, Bustamante-Ogando JC, et al. Expanding the horizons of CAR-T cell therapy: A review of therapeutic targets across diverse diseases. Pharmaceuticals (Basel). 2025;18(2):156.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3282_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X, et al. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"3282_CR20","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhou K, Hu Y, et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 2024;10(12):1681\u20138.","journal-title":"JAMA Oncol"},{"key":"3282_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","volume":"18","author":"J Wei","year":"2021","unstructured":"Wei J, Guo Y, Wang Y, et al. Clinical development of CAR T cell therapy in china: 2020 update. Cell Mol Immunol. 2021;18:792\u2013804.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"3282_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","volume":"108","author":"W Sun","year":"2023","unstructured":"Sun W, Liang AB, Huang H, et al. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023;108(8):2011\u201328.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"3282_CR23","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood-2021-150124","volume":"138","author":"W Chen","year":"2021","unstructured":"Chen W, Fu C, Cai Z, et al. Sustainable efficacy and safety results from lummicar study 1: A phase 1\/2 study of fully human B-Cell maturation Antigen-Specific CAR T cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma. Blood. 2021;138(Supplement 1):2821.","journal-title":"Blood"},{"issue":"1","key":"3282_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.phymed.2009.07.003","volume":"17","author":"CZ Wang","year":"2010","unstructured":"Wang CZ, Li XL, Wang QF, et al. Selective fraction of scutellaria baicalensis and its chemopreventive effects on MCF-7 human breast cancer cells. Phytomedicine. 2010;17(1):63\u20138.","journal-title":"Phytomedicine"},{"key":"3282_CR25","doi-asserted-by":"publisher","first-page":"110917","DOI":"10.1016\/j.biopha.2020.110917","volume":"133","author":"H Liao","year":"2021","unstructured":"Liao H, Ye J, Gao L, et al. The main bioactive compounds of scutellaria baicalensis Georgi for alleviation of inflammatory cytokines: A comprehensive review. Biomed Pharmacother. 2021;133:110917.","journal-title":"Biomed Pharmacother"},{"key":"3282_CR26","doi-asserted-by":"publisher","first-page":"155979","DOI":"10.1016\/j.phymed.2024.155979","volume":"134","author":"Y Liu","year":"2024","unstructured":"Liu Y, Jia Z, Wang Y, et al. Exploring the mechanisms of Huangqin Qingfei Decoction on acute lung injury by LC-MS combined network Pharmacology analysis. Phytomedicine. 2024;134:155979.","journal-title":"Phytomedicine"},{"issue":"2","key":"3282_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","volume":"177","author":"AG Jarnicki","year":"2006","unstructured":"Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4\u2009+\u2009and CD8\u2009+\u2009regulatory T cells. J Immunol. 2006;177(2):896\u2013904.","journal-title":"J Immunol"},{"key":"3282_CR28","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1155\/2015\/102021","volume":"2015","author":"Y Zou","year":"2015","unstructured":"Zou Y, Li WY, Wan Z, et al. Huangqin-Tang ameliorates TNBS-Induced colitis by regulating effector and regulatory CD4(+) T cells. Biomed Res Int. 2015;2015:102021.","journal-title":"Biomed Res Int"},{"issue":"1","key":"3282_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/CBM-170673","volume":"22","author":"G Su","year":"2018","unstructured":"Su G, Chen H, Sun X, et al. Baicalein suppresses Non small cell lung cancer cell proliferation, invasion and Notch signaling pathway. Cancer Biomark. 2018;22(1):13\u20138.","journal-title":"Cancer Biomark"},{"key":"3282_CR30","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.12659\/MSM.909627","volume":"24","author":"J You","year":"2018","unstructured":"You J, Cheng J, Yu B, et al. Baicalin, a Chinese herbal medicine, inhibits the proliferation and migration of human Non-Small cell lung carcinoma (NSCLC) cells, A549 and H1299, by activating the SIRT1\/AMPK signaling pathway. Med Sci Monit. 2018;24:2126\u201333.","journal-title":"Med Sci Monit"},{"issue":"4","key":"3282_CR31","doi-asserted-by":"publisher","first-page":"BSR20181692","DOI":"10.1042\/BSR20181692","volume":"39","author":"X Diao","year":"2019","unstructured":"Diao X, Yang D, Chen Y, et al. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase\/T-LAK cell-originated protein kinase. Biosci Rep. 2019;39(4):BSR20181692.","journal-title":"Biosci Rep"},{"key":"3282_CR32","doi-asserted-by":"crossref","unstructured":"Xiong T, Wang G, Yu P et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. J Clin Invest 2025 Jun 5:e189920.","DOI":"10.1172\/JCI189920"},{"issue":"15","key":"3282_CR33","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.3390\/cancers14153618","volume":"14","author":"BK Lee","year":"2022","unstructured":"Lee BK, Wan Y, Chin ZL, et al. Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies. Cancers (Basel). 2022;14(15):3618.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3282_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/1759-7714.14375","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Chen F, Li J, et al. CAR-T cell therapy for lung cancer: potential and perspective. Thorac Cancer. 2022;13(7):889\u201399.","journal-title":"Thorac Cancer"},{"issue":"6","key":"3282_CR35","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/ijms23063154","volume":"23","author":"X Si","year":"2022","unstructured":"Si X, Xiao L, Brown CE, et al. Preclinical evaluation of CAR T cell function: in vitro and in vivo models. Int J Mol Sci. 2022;23(6):3154.","journal-title":"Int J Mol Sci"},{"key":"3282_CR36","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18:1085\u201395.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"3282_CR37","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, An JY, Lee J, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020;9(5):3367\u201374.","journal-title":"Transl Cancer Res"},{"issue":"10","key":"3282_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","volume":"28","author":"A Couzinet","year":"2024","unstructured":"Couzinet A, Suzuki T, Nakatsura T, et al. Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. Expert Opin Ther Targets. 2024;28(10):895\u2013909.","journal-title":"Expert Opin Ther Targets"},{"key":"3282_CR39","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3389\/fimmu.2018.01364","volume":"9","author":"T Komai","year":"2018","unstructured":"Komai T, Inoue M, Okamura T, et al. Transforming growth Factor-\u03b2 and Interleukin-10 synergistically regulate humoral immunity via modulating metabolic signals. Front Immunol. 2018;9:1364.","journal-title":"Front Immunol"},{"issue":"12","key":"3282_CR40","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Wu F, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10(12):918.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3282_CR41","doi-asserted-by":"publisher","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","volume":"10","author":"D Kyuno","year":"2022","unstructured":"Kyuno D, Takasawa A, Takasawa K, et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022;10(1):1967080.","journal-title":"Tissue Barriers"},{"issue":"6","key":"3282_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in Gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398.","journal-title":"Nat Med"},{"issue":"12","key":"3282_CR43","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","volume":"9","author":"Y Hu","year":"2022","unstructured":"Hu Y, Feng J, Gu T, et al. CAR T-cell therapies in china: rapid evolution and a bright future. Lancet Haematol. 2022;9(12):e930\u201341.","journal-title":"Lancet Haematol"},{"issue":"3","key":"3282_CR44","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3892\/ijo.2013.1777","volume":"42","author":"CZ Wang","year":"2013","unstructured":"Wang CZ, Calway TD, Wen XD, et al. Hydrophobic flavonoids from scutellaria baicalensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway. Int J Oncol. 2013;42(3):1018\u201326.","journal-title":"Int J Oncol"},{"key":"3282_CR45","doi-asserted-by":"crossref","unstructured":"Erbe H-H, Gingras D, Schuett OE et al. Cost Reducing Engineering Strategies in the Automotive Industry. IFAC Proceedings Volumes. 2004;37(5):305\u2013310.","DOI":"10.1016\/S1474-6670(17)32385-6"},{"issue":"4","key":"3282_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11427-016-5034-5","volume":"59","author":"C Luo","year":"2016","unstructured":"Luo C, Wei J, Han W, et al. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. Sci China Life Sci. 2016;59(4):349\u201359.","journal-title":"Sci China Life Sci"},{"key":"3282_CR47","unstructured":"Yang J et al. Qingdao\u2019s first case! A compensation of 500,000 yuan [Internet]. Toutiao. 2024 Jun 19 [cited 2025 Jun 25]. Available from: https:\/\/www.toutiao.com\/article\/7147497472150012448\/?upstream_biz=doubao&source=m_redirect"},{"key":"3282_CR48","unstructured":"[No author listed]. Hu Huibao has provided supplementary medical security for over 20 million people, with compensation exceeding 1.5 billion yuan [Internet]. Toutiao. 2024 Jun 20 [cited 2025 Jun 25]. Available from: https:\/\/www.toutiao.com\/article\/7341232739796582924\/?upstream_biz=doubao&source=m_redirect"},{"key":"3282_CR49","unstructured":"Hu XL et al. Further opening-up key to attracting, keeping intl investment. Chin Daily. 2024 Jan 22. Available from: https:\/\/www.chinadaily.com.cn\/a\/202401\/22\/WS65add6b8a3105f21a507d935.html"},{"key":"3282_CR50","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1007\/s12668-024-01389-x","volume":"14","author":"H Mellatyar","year":"2024","unstructured":"Mellatyar H, Sattari S, Asl AN, et al. Recent advances and challenges in cancer treatment with CAR T cell therapy: A novel Anti-cancer strategy. BioNanoSci. 2024;14:4250\u201362.","journal-title":"BioNanoSci"},{"issue":"1","key":"3282_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10571-024-01499-w","volume":"44","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li T, Wang G, et al. Advancements in Single-Cell RNA sequencing and Spatial transcriptomics for central nervous system disease. Cell Mol Neurobiol. 2024;44(1):65.","journal-title":"Cell Mol Neurobiol"},{"key":"3282_CR52","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541.","journal-title":"Sci Rep"},{"key":"3282_CR53","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.ctrv.2021.102240","volume":"99","author":"SM Lim","year":"2021","unstructured":"Lim SM, Pyo KH, Soo RA, et al. The promise of bispecific antibodies: clinical applications and challenges. Cancer Treat Rev. 2021;99:102240.","journal-title":"Cancer Treat Rev"},{"key":"3282_CR54","doi-asserted-by":"publisher","first-page":"18994","DOI":"10.1038\/s41598-024-70073-7","volume":"14","author":"YH Li","year":"2024","unstructured":"Li YH, Li YL, Wei MY, et al. Innovation and challenges of artificial intelligence technology in personalized healthcare. Sci Rep. 2024;14:18994.","journal-title":"Sci Rep"},{"issue":"6","key":"3282_CR55","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21(6):451\u201372.","journal-title":"Cancer Biol Med"},{"issue":"10","key":"3282_CR56","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Chen TW, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385.","journal-title":"Ann Oncol"},{"issue":"22","key":"3282_CR57","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS, et al. CAR T cells and T-Cell therapies for cancer: A translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"key":"3282_CR58","doi-asserted-by":"publisher","first-page":"927132","DOI":"10.3389\/fimmu.2022.927132","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, Zhang Y, Ji N, et al. Challenges in the treatment of glioblastoma by chimeric antigen receptor T-Cell immunotherapy and possible solutions. Front Immunol. 2022;13:927132.","journal-title":"Front Immunol"},{"key":"3282_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40290-015-0117-3","volume":"29","author":"PJ Harris","year":"2015","unstructured":"Harris PJ, Shaw IC, et al. The contrasting medicines regulatory environments of China and the Western world. Pharm Med. 2015;29:319\u201322.","journal-title":"Pharm Med"},{"issue":"2","key":"3282_CR60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s43441-022-00472-3","volume":"57","author":"L Su","year":"2023","unstructured":"Su L, Liu S, Li G, et al. Trends and characteristics of new drug approvals in china, 2011\u20132021. Ther Innov Regul Sci. 2023;57(2):343\u201351.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03282-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:34:05Z","timestamp":1757421245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03282-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics,<!--Emphasis Type='Bold' removed--> consent to participate,<!--Emphasis Type<!--Too long, content removed-->"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Clinical trial number"}}],"article-number":"1593"}}